Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation

NCT05877599 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05877599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05877599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1, Multicentre Platform Study to Evaluate the Safety and Preliminary Anti-tumour Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Participants With Advanced Malignancies That Are Positive for the TP53 R175H Mutation
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Recruiting
Start date
July 12, 2023
Completion date
July 31, 2029
Enrollment
45 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal carcinoma, head and neck squamous cell carcinoma, myeloid neoplasms (aml/mds), non-small cell lung cancer, other solid tumors, ovarian cancer, pancreatic adenocarcinoma